Literature DB >> 27260946

PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.

Zhongwu Li1, Yumei Lai1, Li Sun1, Xiaotian Zhang2, Ruping Liu3, Guoshuang Feng4, Lixin Zhou1, Lin Jia1, Xiaozheng Huang1, Qiang Kang1, Dongmei Lin1, Jing Gao5, Lin Shen6.   

Abstract

The mechanism of carcinogenesis of gastric cancer (GC) is still unclear now. This study aimed to explore the correlations among PD-L1, Epstein-Barr virus (EBV) infection, lymphocyte infiltration, HER2 expression, HER2 gene status, histology, and other clinicopathological factors in GC. A total of 44 GC patients with massive lymphocyte infiltration (GC-MLI) and 93 GC patients without massive lymphocyte infiltration were involved in this study. Immunohistochemical analysis was used to test the expression levels of PD-L1 and HER2. Fluorescence in situ hybridization was used on HER2-positive cases with a score of 2+ to test the HER2 gene status. EBV-encoded RNA was used to test for EBV infection. In univariate analysis, PD-L1 expression was significantly associated with GC-MLI (P<.001), lower age (P=.019), EBV infection (P<.001), lower HER2 expression (P=.011), and diffuse/mixed type of histology (P=.022). EBV-encoded RNA-positive cases were significantly associated with GC-MLI (P<.001), lower age (P=.016), diffuse/mixed type of histology (P=.011), and lower HER2 expression (P=.032). In the multivariate logistic regression model, GC-MLI and the diffuse/mixed type histology were identified as 2 independent factors that affected PD-L1 expression (P<.001). Furthermore, PD-L1-positive cases have worse overall survival than do PD-L1-negative cases (P=.011). These results suggest that massive lymphocyte infiltration and the diffuse/mixed type histology of GC should be taken into consideration to select the appropriate patients for PD-L1 inhibitory treatment in the future.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EBV; Gastric cancer; HER2; PD-L1; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 27260946     DOI: 10.1016/j.humpath.2016.05.012

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  33 in total

1.  Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.

Authors:  Simon Pernot; Magali Terme; Nina Radosevic-Robin; Florence Castan; Cécile Badoual; Elie Marcheteau; Fréderique Penault-Llorca; Olivier Bouche; Jaafar Bennouna; Eric Francois; Francois Ghiringhelli; Christelle De La Fouchardiere; Emmanuelle Samalin; Jean Baptiste Bachet; Christophe Borg; Valérie Boige; Thibault Voron; Trevor Stanbury; Eric Tartour; Sophie Gourgou; David Malka; Julien Taieb
Journal:  Gastric Cancer       Date:  2019-07-02       Impact factor: 7.370

2.  In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.

Authors:  Yanhua Bai; Ting Guo; Xiaozheng Huang; Qi Wu; Dongfeng Niu; Xinqiang Ji; Qin Feng; Zhongwu Li; Kennichi Kakudo
Journal:  Virchows Arch       Date:  2018-04-12       Impact factor: 4.064

3.  Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact.

Authors:  Joo Yeon Kim; Woo Gyeong Kim; Chae Hwa Kwon; Do Youn Park
Journal:  Gastric Cancer       Date:  2019-05-31       Impact factor: 7.370

4.  CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8+/Foxp3+ T cells.

Authors:  Hiroyuki Abe; Ruri Saito; Takashi Ichimura; Akiko Iwasaki; Sho Yamazawa; Aya Shinozaki-Ushiku; Teppei Morikawa; Tetsuo Ushiku; Hiroharu Yamashita; Yasuyuki Seto; Masashi Fukayama
Journal:  Virchows Arch       Date:  2018-03-13       Impact factor: 4.064

5.  Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.

Authors:  Jie Shi; Xu Yang; Xinmei Wang; Yufeng Luo; Weixun Zhou; Hanhuan Luo; Zhaxi Bianba; Zhuoma Nima; Qian Wang; Han Wang; Ruiqian Liao; Quzhen Ciren; Mei Li; Junyi Pang
Journal:  Biomed Res Int       Date:  2022-06-13       Impact factor: 3.246

6.  New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.

Authors:  Irene Gullo; Patrícia Oliveira; Maria Athelogou; Gilza Gonçalves; Marta L Pinto; Joana Carvalho; Ana Valente; Hugo Pinheiro; Sara Andrade; Gabriela M Almeida; Ralf Huss; Kakoli Das; Patrick Tan; José C Machado; Carla Oliveira; Fátima Carneiro
Journal:  Gastric Cancer       Date:  2018-05-19       Impact factor: 7.370

7.  CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.

Authors:  Yunfei Shi; Lijuan Deng; Yuqin Song; Dongmei Lin; Yumei Lai; LiXin Zhou; Lei Yang; Xianghong Li
Journal:  Int J Hematol       Date:  2018-05-10       Impact factor: 2.490

8.  Gastric Carcinomas With Lymphoid Stroma: Categorization and Comparison With Solid-Type Colonic Carcinomas.

Authors:  Raul S Gonzalez; Justin M M Cates; Frank Revetta; Loralee A McMahon; Kay Washington
Journal:  Am J Clin Pathol       Date:  2017-11-20       Impact factor: 2.493

9.  Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis.

Authors:  Zhebing Qiu; Yinguo Du
Journal:  J Gastrointest Oncol       Date:  2021-02

10.  Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.

Authors:  Ramy R Saleh; Jordan L Scott; Nicholas Meti; Danielle Perlon; Rouhi Fazelzad; Alberto Ocana; Eitan Amir
Journal:  Mol Diagn Ther       Date:  2022-02-01       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.